PEAK6 Investments’s Madrigal Pharmaceuticals MDGL Stock Holding History

PEAK6 Investments’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$361K	Sell	1,700 -5,800	-77%	-$1.48M	﹤0.01%	2499
2024 Q2	$2.1M	Buy	7,500 +6,800	+971%	+$1.62M	0.01%	1339
2024 Q1	$187K	Sell	700 -2,300	-77%	-$542K	﹤0.01%	3099
2023 Q4	$694K	Buy	3,000 +1,700	+131%	+$297K	﹤0.01%	2374
2023 Q3	$190K	Sell	1,300 -16,800	-93%	-$3.16M	﹤0.01%	3097
2023 Q2	$4.18M	Sell	18,100 -1,100	-6%	-$298K	0.02%	747
2023 Q1	$4.65M	Sell	19,200 -8,700	-31%	-$2.37M	0.02%	746
2022 Q4	$8.1M	Buy	+27,900	New	+$2.73M	0.05%	462
2022 Q3	–	Sell	-18,100	Closed	-$4.18M	–	5637
2022 Q2	$4.18M	Buy	+18,100	New	+$1.33M	0.01%	1539

Other funds holding MDGL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PEAK6 Investments's MDGL Position: Q3 2024 in Review

PEAK6 Investments opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2024: 27 shares worth $5.73K. The stake represents ﹤0.01% of the portfolio and ranks #3266 among its holdings. This is a return to the name: PEAK6 Investments previously reported a position in MDGL as recently as Q1 2024.

PEAK6 Investments first reported a position in MDGL in Q3 2018 and has held it in 8 quarters since. The position peaked at $505K in Q2 2023. 257 funds tracked by Wall St. Rank hold MDGL as of Q3 2024.

PEAK6 Investments held 27 shares of Madrigal Pharmaceuticals worth $5.73K as of Q3 2024.
Madrigal Pharmaceuticals was a new PEAK6 Investments position in Q3 2024.
Madrigal Pharmaceuticals made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #3266 holding.
PEAK6 Investments first reported a position in Madrigal Pharmaceuticals in Q3 2018 and has held it in 8 quarters since.
PEAK6 Investments's Madrigal Pharmaceuticals position peaked at $505K in Q2 2023.
257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.